Report DMCA Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.